Home / Patients Family / Academy / Digital Academy

Digital Academy

 

MDF community members living with DM and their caregivers present on current symptom management strategies for living with DM, and what they would like to see in clinically-meaningful therapies. Dr. Jonathan Goldsmith, M.D., FACP, head of the Office of Rare Diseases at the FDA, provided a summary of the proceedings and what the FDA took away from the patient input shared at this meeting – at the 2016 DM Patient-Focused Drug Development meeting, a component of the 2016 MDF Annual Conference.

 

MDF community members living with DM, and their caregivers present on the impacts of DM on daily living, in response to specific questions posed by the Food and Drug Administration, which is in charge of reviewing and approving therapies in the U.S. Dr. Janet Woodcock, M.D., who leads all drug evaluation and research at the FDA, also provided remarks – at the 2016 DM Patient-Focused Drug Development meeting, a component of the 2016 MDF Annual Conference.

 

Drs. Laurence Mignon, Ph.D., director of clinical development at Ionis Pharmaceuticals, and Michael Horrigan, M.D., chief medical officer at AMO Pharma, present updates on the status of Phase I/II clinical trials current underway at their industry institutions for potential DM1 therapies – at the 2016 MDF Annual Conference.

 

Drs. John Day, M.D., Ph.D, of Stanford University, Chad Heatwole, M.D., of the University of Rochester and Giovanni Meola, M.D., of the University of Milan present an overview of DM-related disease impacts and symptoms, and the current status of brain-related DM research – at the 2016 MDF Annual Conference.

Mid-Year Legislative Webinar that includes an update on DM research funding requests to the NIH & DoD research programs, information on what Congress is likely to do next, and facts to help you advocate for DM funding.

Partners

© Myotonic Dystrophy Foundation. All rights reserved.